E. Merck KG has appointed Stefan Oschmann as new chairman of the Executive Board and CEO of Merck KGaA, effective April 29, 2016. Stefan Oschmann will succeed Karl-Ludwig Kley, who will retire after then nine years as head of Merck KGaA. E. Merck KG combines the financial interests of the Merck family and, holding an interest of around 70%, is general partner of Merck KGaA.
Stefan Oschman has been a member of the Executive Board of Merck KGaA since 2011. He was initially in charge of the pharma business before being appointed as deputy chairman of the Executive Board and Deputy CEO at the beginning of 2015, responsible for strategy and innovation.
Prior to joining Merck KGaA, Stefan Oschmann worked for more than 20 years for the pharmaceutical company MSD Merck Sharp & Dohme (in the US, Merck & Co. Inc). He is president of the IFPMA (International Federation of Pharmaceutical Manufacturers & Associations) and vice president of EFPIA (European Federation of Pharmaceutical Industries and Associations).
Karl-Ludwig Kley has been a member of the Supervisory Board of Merck KGaA and the Board of Partners of E. Merck KG since 2004. In 2006, he became deputy chairman of the Executive Board of Merck KGaA before taking over as chairman in 2007. Prior to that, he was chief financial officer at Deutsche Lufthansa for eight years and joined the airline’s supervisory board in 2013. He is Deputy Chairman of the supervisory board of BMW and member of the supervisory board of Bertelsmann. In addition, he is vice president of the German Chemicals Association (VCI) and member of the steering committee of the Federation of German Industries (BDI),
Source: Merck KGaA